POMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare Solutions

Company emphasizes the expanding applications of real-world data in medical research, clinical decision-making, healthcare payment and personalized treatment

GUANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted the growing strategic importance of its real-world data ("RWD") assets in transforming healthcare delivery and decision-making, as well as the Company's initiatives to develop its RWD capabilities as a foundation for advancing predictive and data-driven healthcare solutions.

As healthcare systems increasingly adopt digital technologies, RWD is evolving from a supplementary information source into an essential resource for evidence-based medical decisions. By capturing continuous health information from clinical practice, wearable devices, medication records and daily activities, RWD aims to provide multidimensional, valuable insights into patient conditions, treatment responses and long-term health outcomes. When systematically collected, integrated and analyzed, these data can help bridge the gap between clinical research and real-world healthcare practice, supporting more informed medical decisions and improved healthcare management.

Expanding Applications of RWD Across Healthcare Ecosystem

RWD is playing an increasingly important role across the healthcare ecosystem, creating opportunities to improve medical research, clinical practice and healthcare resource allocation.

In pharmaceutical research and development, real-world studies ("RWS") based on RWD can complement clinical trials by providing additional insights into treatment effectiveness, medication adherence and long-term patient outcomes. Such evidence can help pharmaceutical companies better understand how treatments perform in routine clinical settings and inform drug development and commercialization strategies.

In clinical practice, RWD can support evidence-based guidelines and help physicians make more informed treatment decisions based on broader patient information and observed treatment outcomes.

In healthcare payment systems, RWD can contribute to evaluating treatment outcomes, cost-effectiveness and healthcare utilization, supporting more informed reimbursement and risk management strategies.

Additionally, when combined with AI-powered analytics, continuous patient data can enable earlier risk identification, personalized treatment plans and more proactive chronic disease management. These capabilities are expected to play an increasingly important role in the transition from reactive treatment toward preventive, predictive and personalized healthcare.

POMDOCTOR's Data-Driven Healthcare Strategy

Building upon its established healthcare platform and physician network, Pomdoctor is advancing an integrated RWD ecosystem encompassing physiological indicators, behavioral patterns, medication records, remote patient monitoring ("RPM") data and healthcare payment-related information.

Through the integration of wearable technologies, AI analytics and physician-led interventions, the Company aims to establish a continuous healthcare data feedback loop connecting health monitoring, risk assessment, personalized intervention and long-term patient management. This integrated approach is intended to transform fragmented healthcare information into structured, actionable insights that can support both individual patient care and broader healthcare applications.

Pomdoctor believes that high-quality, multidimensional healthcare data represents one of its critical competitive advantages in the digital healthcare era. By continuously accumulating and analyzing real-world healthcare information, the Company seeks to strengthen its AI capabilities, enhance clinical decision support and support the commercialization of RWD applications, including pharmaceutical research collaborations and enterprise healthcare data services.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented, "We believe RWD is an increasingly important cornerstone for next generation healthcare services. At Pomdoctor, we are integrating AI, wearable technologies and healthcare data to transform fragmented medical information into actionable insights that can support more informed and personalized healthcare decisions. We are confident that our expanding data capabilities will support more personalized, predictive and efficient healthcare services while creating meaningful long-term value across the healthcare ecosystem."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company in China that operates an internet hospital platform for chronic diseases and a pharmaceutical supply chain business, which together have historically generated revenues primarily from sales of pharmaceutical products and related healthcare services. The Company is currently focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company seeks to leverage physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company's strategic evolution from a traffic monetization model toward value-based healthcare payment and monetization; the Company's plans to further strengthen its four-tier revenue structure spanning B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services, and to integrate these businesses into a more comprehensive healthcare ecosystem; the Company's development and piloting of AI-enabled healthcare programs and its ability to convert clinical applications into scalable, revenue-generating services; the Company's plans to integrate AI technologies, wearable devices and its existing digital healthcare infrastructure, and its belief that such integration can progressively transform data assets into sources of incremental commercial value; the Company's expectations regarding growth in recurring subscription revenue, the expansion of its institutional reach and relationships with healthcare institutions, including public hospitals, and pharmaceutical companies, and the development of higher-value pharmaceutical RWS/RWD services; the Company's belief that its interconnected business model is designed to balance near-term revenue generation and cash flow with longer-term growth opportunities and to create a potential flywheel effect; the Company's exploration of opportunities to replicate and adapt its business model in key international markets; and the anticipated benefits of the Company's strategy for patients, healthcare providers, pharmaceutical companies, shareholders and other ecosystem participants, including sustainable long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "aims," "estimates," "projects," "intends," "plans," "pursues," "positions," "will," "would," "should," "could," "may" or other similar expressions. These forward-looking statements are based on the Company's current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties, including, without limitation: the risk that the Company's AI-enabled healthcare initiatives, including its AI chronic disease management system, AI analytics and RWD capabilities, may not be successfully developed, validated, deployed or commercialized on the anticipated timeline or at all; evolving PRC and other laws and regulations governing AI, internet healthcare, medical devices, healthcare data, personal information protection, data security and cross-border data transfers, including restrictions on the Company's ability to collect, use, de-identify or commercialize RWD; cybersecurity incidents and data breaches; and competition from other companies with AI, technology and data resources. Investors are urged to review the section entitled "Item 3. Key Information—D. Risk Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2026, and the Company's other filings with the SEC, which are available on the SEC's website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

SOURCE POMDOCTOR LIMITED